Severe neurologic effects, including blindness, coma, and death were observed in dose-ranging studies in patients with acute leukemia when fludarabine phosphate was administered at high doses.
Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported after one or more cycles of treatment with fludarabine phosphate.
- TRADE NAMES: Fludara (Genzyme); Oforta (Sanofi-Aventis)
- INDICATIONS: Chronic lymphocytic leukemia (B-cell)
- CLASS: Antimetabolite, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: 9 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Clofazimine, Live vaccines, Pentostatin
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
CNS TOXICITY, HEMOLYTIC ANEMIA, AND PULMONARY TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
